CEP1612
CEP1612 is a dipeptidyl proteasome inhibitor with the IC50 of 60 nM. CEP1612 induces p21 (WAF1) and p27 (KIP1) expression and cell apoptosis. CEP1612 shows anticancer activity in vivo[1][2].
Product Specifications
CAS Number
189036-01-9
UNSPSC
12352005
Target
Apoptosis; Proteasome
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cep1612.html
Smiles
O=C1C2=CC=CC=C2C(N1CCCCCCCCC(C3CCCC3)C(N[C@@H](CCCNC(NN(=O)=O)=N)C(N[C@H](C=O)CC(C)C)=O)=O)=O
Molecular Formula
C35H53N7O7
Molecular Weight
683.84
References & Citations
[1]Sun J, et al. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 2001;61 (4) :1280-1284. |[2]An B, et al. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998;5 (12) :1062-1075.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
